Advertisement
News
Advertisement

Alnylam to start Phase 2 trials of ATTR treatment

Fri, 06/08/2012 - 12:31am
Mass High Tech: The Journal of New England Technology

Cambridge-based Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), a company that aims to treat diseases by moderating the genes in living cells, announced that it began a Phase 2 trial of a drug candidate to treat transthyretin-mediated amyloidosis (ATTR), a hereditary disease that can damage the heart and nervous system.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading